FDA's PDUFA VIII adds 'America First' incentives and speeds up drug reviews

The Food and Drug Administration announced the next five‑year reauthorization of the Prescription Drug User Fee Act, known as PDUFA VIII. The agency said the new framework will introduce several policy changes aimed at strengthening the domestic pharmaceutical sector.

Among the key provisions are incentives that favor U.S.-based drug makers, encouraging them to develop and manufacture products within the United States. The FDA also plans to streamline certain review processes, offering faster timelines for qualifying applications.

In addition, the agency intends to improve communication channels with industry stakeholders, providing clearer guidance and more responsive interaction throughout the regulatory pathway.